Action potential simulation (APS) therapy for pain in people with MS: results of a three year pilot study
Author(s): ,
E.S Matthews
Affiliations:
Neurology, Northampton District General Hospital, Northampton
,
E.M Olding
Affiliations:
MS Specialist Nursing
,
D Kehoe
Affiliations:
Beds and Northants MS Therapy Centre, Bedford
,
H Raisin
Affiliations:
Beds and Northants MS Therapy Centre, Bedford
,
E Burgess
Affiliations:
Psychology, University of Hatfield, Hatfield, United Kingdom
R.J Olding
Affiliations:
Beds and Northants MS Therapy Centre, Bedford
ECTRIMS Online Library. Olding E. Sep 14, 2016; 145473; EP1377
E. Miranda Olding
E. Miranda Olding
Contributions
×
Abstract

Abstract: EP1377

Type: ePoster

Abstract Category: Clinical aspects of MS - MS symptoms

People with MS commonly suffer from both nociceptive and neuropathic pain, and the latter is often resistant to treatment, or hard to resolve due to the unwanted side-effects of most of the appropriate drugs.

We report on a three year pilot study, using the micro-current electrotherapy device Action Potential Simulation (APS) Therapy to treat pain in people with MS, at a multi-disciplinary MS Therapy Centre, in Bedford, UK. 2 year data is below; 3 year data will be reported at ECTRIMS 2016.

APS Therapy sends waves of simulated action potentials through the cells of the body, modelling correct neuro-transmission, enhancing cellular communication, and stimulating the production and release of adenosine triphosphate and other neurohormones and neurotransmitters.

An 8 week course of the therapy 3 times a week was offered initially, and 60 people used APS Therapy to treat 94 different pains. Visual Analogue Scale (VAS) for pain was used to assess pain prior to starting treatment, and measured weekly thereafter.

47 people (78%) had a significant reduction in pain. Of the 94 pains, 75 (80%) had a reduction of at least one point on the VAS for usual level of pain. The average reduction in points on the VAS was 3.04 for "usual pain", and 4.87 for "worst pain". 31 "usual pain" scores (33%) were reduced to pain free.

33 people (57%) reduced or discontinued analgesic medications as a result of the effects of APS Therapy, and 33 people (57%) went onto long term maintenance therapy.

Our paper examines the results for pain of different types and origins, for example, neuropathic pain of feet and legs, back pain, headaches.

Many participants reported other unexpected benefits of treatment, which impacted positively on their quality of life, including improvements in mobility and stiffness, sleep quality, energy levels and wellbeing.

Visual Analogue Scale (VAS) was used as an outcome measure throughout. During the second year, the Brief Pain Inventory and Pittsburgh Sleep quality index were also adopted to record the impact of pain relief on quality of life, and improvements in sleep.

Results in the 2nd year were consistent with the 1st, and we aim to have ready the 3rd year of data for ECTRIMS 2016.

We are aware of the limitations of this small pilot study, but hope that by presenting it, we can stimulate further clinical use and research.

Disclosure: Miranda Olding: since commencing the pilot study, I have become the UK trainer and distributor for APS Therapy, and run this business alongside my role as an MS Specialist Nurse.

Emma Matthews: nothing to declare

Denice Kehoe: nothing to declare

Heather Raisin: nothing to declare

Emma Burgess: nothing to declare

Rose Olding: nothing to declare

There was no funding for this project.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies